Stephen Sanders

Array ( [id] => 17921665 [patent_doc_number] => 11464886 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Controllable self-annealing microgel particles for biomedical applications [patent_app_type] => utility [patent_app_number] => 17/144158 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 49 [patent_no_of_words] => 20592 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807862 [patent_doc_number] => 20210130415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => CHEMICALLY-MODIFIED ADENO-ASSOCIATED VIRUS [patent_app_type] => utility [patent_app_number] => 17/142276 [patent_app_country] => US [patent_app_date] => 2021-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17142276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18237819 [patent_doc_number] => 20230070129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING MACULAR DEGENERATION, CONTAINING CELL PERMEABLE NUCLEIC ACID COMPLEX AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 17/790734 [patent_app_country] => US [patent_app_date] => 2021-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17790734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922953 [patent_doc_number] => 20240025957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => Insulin Derivative [patent_app_type] => utility [patent_app_number] => 17/758108 [patent_app_country] => US [patent_app_date] => 2020-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036751 [patent_doc_number] => 20210253709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => PD-L 1-BINDING POLYPEPTIDE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/137188 [patent_app_country] => US [patent_app_date] => 2020-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14992 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17137188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207217 [patent_doc_number] => 20230053473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/789099 [patent_app_country] => US [patent_app_date] => 2020-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207217 [patent_doc_number] => 20230053473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/789099 [patent_app_country] => US [patent_app_date] => 2020-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17789099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932424 [patent_doc_number] => 20210198313 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => METHOD OF PRODUCING IMIDAZOLE DIPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/134185 [patent_app_country] => US [patent_app_date] => 2020-12-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17134185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146235 [patent_doc_number] => 20230020092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/757421 [patent_app_country] => US [patent_app_date] => 2020-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17757421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146235 [patent_doc_number] => 20230020092 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/757421 [patent_app_country] => US [patent_app_date] => 2020-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17757421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18181447 [patent_doc_number] => 20230042176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/786384 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17786384 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436016 [patent_doc_number] => 20230183310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications [patent_app_type] => utility [patent_app_number] => 17/801465 [patent_app_country] => US [patent_app_date] => 2020-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18162594 [patent_doc_number] => 20230029187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2 [patent_app_type] => utility [patent_app_number] => 17/778823 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921409 [patent_doc_number] => 20240024413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => COMPOSITION AND METHOD FOR TREATMENT OF ISCHEMIC DISEASE [patent_app_type] => utility [patent_app_number] => 18/038686 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921409 [patent_doc_number] => 20240024413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => COMPOSITION AND METHOD FOR TREATMENT OF ISCHEMIC DISEASE [patent_app_type] => utility [patent_app_number] => 18/038686 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18038686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656062 [patent_doc_number] => 20210052698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/091500 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168848 [patent_doc_number] => 20210322518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => XTEN CONJUGATE COMPOSITIONS AND METHODS OF MAKING SAME [patent_app_type] => utility [patent_app_number] => 17/084082 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 135697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -140 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428760 [patent_doc_number] => 11673970 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Bi-specific fusion proteins [patent_app_type] => utility [patent_app_number] => 17/078978 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 14096 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17078978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20329707 [patent_doc_number] => 12459973 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-04 [patent_title] => Peptide compounds for reducing side effects of CB1 receptor agonists [patent_app_type] => utility [patent_app_number] => 17/766355 [patent_app_country] => US [patent_app_date] => 2020-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 2333 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870544 [patent_doc_number] => 20210164011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME [patent_app_type] => utility [patent_app_number] => 17/036396 [patent_app_country] => US [patent_app_date] => 2020-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17036396 [rel_patent_id] =>[rel_patent_doc_number] =>)